Affirma Biotech is focused on developing a new generation of orally available immunotherapeutic drugs aimed at treating severe infections and cancer. The company has made significant advancements in medicinal chemistry, resulting in the discovery of a family of novel small molecules that act as immune system activators. These compounds are designed to stimulate the immune response, particularly by reinvigorating exhausted T-cells, and are intended for broad-spectrum application against various infectious diseases, including severe influenza and chronic hepatitis B. The innovative approach of using immune activation in the treatment of infectious diseases represents a shift from traditional antiviral and antibacterial therapies, addressing the urgent need for effective treatments in the face of rising antimicrobial resistance.

Affirma Biotech has secured substantial funding to support its research and development efforts, including a recent €1.75 million investment aimed at advancing its candidates for viral and bacterial infections. The company is collaborating with the University of Barcelona and IS Global to explore new immunomodulatory therapies, and it has received grants from the Spanish State Research Agency and CDTI to further its projects. With a strong management team and a commitment to innovation, Affirma Biotech aims to initiate clinical trials within the next two years, with the potential to significantly impact global health by providing new therapeutic options for diseases that currently lack effective treatments.

Spain

Affirma Biotech is a privately owned preclinical company that develops new orally available immunotherapeutic drugs for the treatment of severe infections.

Affirma Biotech

Company Details